IMPACT OF VARIANTS OF UNCERTAIN SIGNIFICANCE ON TELOMERE BIOLOGY DISORDERS: A SINGLE CENTER EXPERIENCE

EHA Library, Luca Arcuri, 4207677

SOVLEPLENIB AMELIORATES APLASTIC ANEMIA THROUGH THE MODULATION OF CGAS-STING-NF-ΚB PATHWAY

EHA Library, Hong Liu, 4207678

LONG-TERM MUTATIONAL ANALYSIS, CLONAL METRICS AND DYNAMICS IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA HIGHLIGHT THE IMPORTANCE OF MOLECULAR MONITORING

EHA Library, Helen Papadaki, 4207679

SAFETY OF RAVULIZUMAB USE IN PREGNANCY: INSIGHTS FROM A GLOBAL PHARMACOVIGILANCE ANALYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Cory Williams, 4207680

PLATELET PNH CLONE ASSESSMENT BY FLOW CYTOMETRY ISFEASIBLE AND PROVIDES A RELIABLE ESTIMATE OF CLONE SIZE AND PLATELET ACTIVATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Lucas Sales, 4207682

3-YEAR EFFICACY AND SAFETY OF CROVALIMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS: LONG-TERM DATA FROM THE PHASE III COMMODORE 2 TRIAL

EHA Library, Naoshi Obara, 4207685

A PROGNOSTIC NORMOGRAM TO ESTIMATE THE SEVERE PHENOTYPE IN PATIENTS WITH FANCONI ANEMIA: A SINGLE-CENTER COHORT STUDY

EHA Library, Beril Kiracı Şen, 4207690

LONGITUDINAL EVALUATION OF CLONAL HEMATOPOIESIS IN BONE MARROW FAILURE AND PRIMARY IMMUNE DYSREGULATION DISORDERS: SINGLE CENTER DATA

EHA Library, Luca Arcuri, 4207694

A MULTICENTER REAL-WORLD STUDY EVALUATING THE EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH AA-PNH SYNDROME

EHA Library, ZHAOXIA LIU, 4207697

CLINICAL SPECTRUM AND MUTATIONAL BURDEN OF PIGA VARIANTS DETECTED BY BONE MARROW NGS: REAL-WORLD DIAGNOSTIC IMPLICATIONS AND CORRELATION WITH PNH CLONE SIZE

EHA Library, Min Wu, 4207699

IMPACT OF IPTACOPAN, A COMPLEMENT INHIBITOR, ON CHINESE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTICENTER RETROSPECTIVE COHORT STUDY

EHA Library, Shuqian Xu, 4207701

EFFICACY AND SAFETY OF ROMIPLOSTIM IN NEWLY DIAGNOSED APLASTIC ANEMIA: REAL-WORLD SINGLE CENTRE EXPERIENCE FROM INDIA

EHA Library, Chaitanya H Balakrishnan, 4207703

GENETIC SUSCEPTIBILITY TO ARTERIAL THROMBOEMBOLISM IN NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE UK NCRI MYELOMA XI TRIAL.

EHA Library, Sina Beer, 4207705

T(8;14) IMPROVES THE IMS/IMWG CONSENSUS GENOMIC STAGING FOR DEFINING HIGH-RISK MULTIPLE MYELOMA PATIENTS

EHA Library, Anaïs Schavgoulidze, 4207707

TARGETING GLUTAMINE METABOLISM AS A NEW STRATEGY TO IMPROVE ANTI-BCMA T CELL ENGAGER ACTIVITY  IN MYELOMA CELLS.

EHA Library, Nicola Giuliani, 4207708

LONGITUDINAL IMMUNE PROFILING REVEALS BASELINE AND ACQUIRED EXTRINSIC DETERMINANTS OF RESISTANCE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jana Mihályová, 4207710

RAS–MAPK MUTATIONAL PROFILE IS ASSOCIATED WITH MULTI-PATHWAY GENOMIC ALTERATIONSAND A DISTINCT TERMINALLY DIFFERENTIATED/EXHAUSTED T-CELL SIGNATURE IN NEWLY DIAGNOSEDMULTIPLE MYELOMA

EHA Library, Paula Piñero, 4207711

ABS CATA-001: A NOVEL CD38/AL BISPECIFIC FOR TREATING  MULTIPLE MYELOMA

EHA Library, Chengcheng Fu, 4207713

A NOVEL CDK9 INHIBITOR, GT-02897, SELECTIVELY INDUCES CYTOTOXIC EFFECTS AND EXHIBITS PRECLINICAL SYNERGISTIC ACTIVITY IN MYELOMA

EHA Library, Osman Aksoy, 4207721

SINGLE CELL RNA SEQUENCING REVEALS IMMUNE MICROENVIRONMENT REMODELING IN PRIMARY PLASMA CELL LEUKEMIA: REAL-WORLD EVIDENCE FROM THE KMMWP-2204 STUDY

EHA Library, Sung-Hoon Jung, 4207722

NUCLEAR DONUT-SHAPED DEFORMATION MARKS MULTIPLE MYELOMA CELL DORMANCY

EHA Library, Mengge Pan, 4207723

CRBN-INDEPENDENT IKZF1 DEGRADATION VIA TRIM21 BY DNA DEMETHYLATING AGENTS AS A NOVEL THERAPEUTIC MECHANISM FOR MULTIPLE MYELOMA

EHA Library, Yuta Yamamoto, 4207725

T CELL MORPHOLOGY PREDICTS OUTCOME IN MULTIPLE MYELOMA USING HIGH-CONTENT IMAGING

EHA Library, Frederik Herzberg, 4207726

GENOMIC LANDSCAPE AND CHARACTERIZATION OF END STAGE MULTIPLE MYELOMA

EHA Library, Julia Wiedmeier-Nutor, 4207727

ANSELAMIMAB TARGETS BOTH CYTOTOXIC SOLUBLE PREFIBRILLAR SPECIES AND INSOLUBLE FIBRILS OF LIGHT CHAIN AMYLOIDOSIS

EHA Library, Sahar Usmani-Brown, 4207728

TRAF2 AND NCK INTERACTING KINASE SIGNALING DRIVES MULTIPLE MYELOMA DEVELOPMENT AND PROGRESSION

EHA Library, Adrian Wegmüller, 4207729

ROLE AND MECHANISM OF PIM-2 KINASE INHIBITOR-INDUCED IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA

EHA Library, Rong Fu, 4207732

PHF19 DRIVES LENALIDOMIDE RESISTANCE BY EPIGENETICALLY REPROGRAMMING THE IRF4/MYC AXIS IN MULTIPLE MYELOMA

EHA Library, Xiyue Sun, 4207733

A NOVEL CIRCULAR RNA PRODUCED BY THE “NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC 3” GENE (CIRCNFATC3), DISCOVERED BY NANOPORE SEQUENCING, HOLDS SIGNIFICANT PROGNOSTIC VALUE IN MULTIPLE MYELOMA

EHA Library, Evangelos Terpos, 4207734

M6A METHYLATION MEDIATES GUICAOBAIDU DECOCTION-INDUCED MITOPHAGY TO ATTENUATE CARFILZOMIB-INDUCED CARDIOTOXICITY

EHA Library, Nayan Yi, 4207736

A COMMON GENE EXPRESSION SIGNATURE ACROSS MULTIPLE MYELOMA DISEASE STAGES IDENTIFIES HIGH-RISK OF DISEASE PROGRESSION

EHA Library, Claudio Cerchione, 4207741

MALONYL-COA–DRIVEN XPO1 MALONYLATION PROMOTES DRUG RESISTANCE THROUGH BECLIN1 NUCLEAR EXPORT–DEPENDENT AUTOPHAGY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Guangqi Wang, 4207742

IMS-IMWG 2025 CONSENSUS GENOMIC STAGING (CGS) OF MULTIPLE MYELOMA IN COMMPASS IDENTIFIES CLINICAL DIFFERENCES AND SURVIVAL DISPARITIES FOR PATIENTS WITH HIGH AFRICAN GENETIC ANCESTRY

EHA Library, Chaitanya Acharya, 4207743

LNCRNA NEAT1 ORCHESTRATES A CERNA NETWORK GOVERNING CORE PATHWAYS OF PROLIFERATION AND CELLULAR DYNAMICS IN MULTIPLE MYELOMA

EHA Library, Niccolò Bolli, 4207746

CXCR4 REWIRES MITOCHONDRIAL FUNCTION TO SUSTAIN METABOLIC PLASTICITY AND SURVIVAL IN MULTIPLE MYELOMA

EHA Library, Katia Beider, 4207748

PHARMACOLOGIC BCMA UPREGULATION WITH ATRA ENHANCES BELANTAMAB MAFODOTIN ACTIVITY IN MULTIPLE MYELOMA

EHA Library, Amaya Llorente, 4207749

DREAMM-9 FINAL ANALYSIS: BELANTAMAB MAFODOTIN (BELAMAF), BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (BVRD) FOR TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Enrique M. Ocio, 4207750

UPDATED RESULTS OF A PHASE 1 FIRST-IN-HUMAN STUDY OF CEMSIDOMIDE, A NOVEL MONODAC® DEGRADER, WITH DEXAMETHASONE (DEX) IN PATIENTS WITH (RRMM)

EHA Library, Sagar Lonial, 4207751

DURABLE CLINICAL BENEFIT WITH B-CELL MATURATION ANTIGEN THERAPY, BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE, IN RELAPSED/​REFRACTORY MULTIPLE MYELOMA: DREAMM‑8 LONG‑TERM RESPONDER ANALYSIS

EHA Library, Meletios Dimopoulos, 4207752

CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA RESPONDING TO BRIDGING THERAPY: CARTITUDE-4 CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, Niels W C J van de Donk, 4207755

VALIDATION OF A MYELOMA ELDERLY PROGNOSTIC SCORE (MEPS) BASED ON FRAILTY AND HIGH-RISK CYTOGENETICS IN TRANSPLANT INELIGIBLE PATIENTS: A COLLABORATION OF THE GREEK AND PORTUGUESE MYELOMA STUDY GROUPS

EHA Library, Eirini Katodritou, 4207756

REVISED DYNAMIC FRAILTY-TAILORED THERAPY (DYNAFIT-V2) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A PROSPECTIVE MULTICENTER STUDY

EHA Library, Fengyan Jin, 4207759

INTEGRATED RISK STRATIFICATION IN MULTIPLE MYELOMA USING SOLUBLE BCMA AND CIRCULATING TUMOR CELLS

EHA Library, Masanori Toho, 4207760

PROMISING PERFORMANCE OF PET/CT USING [68GA]GA-PENTIXAFOR FOR INITIAL STAGING AND THERAPEUTIC EVALUATION OF MULTIPLE MYELOMA PATIENTS IN FIRST LINE TREATMENT OR RELAPSE: INTERIM ANALYSIS.

EHA Library, Caroline Milin, 4207761

ELRANATAMAB IN COMBINATION WITH DARATUMUMAB AND LENALIDOMIDE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: RESULTS FROM MAGNETISMM-6 PART 1

EHA Library, Carmine Liberatore, 4207762

PFS2 OUTCOMES BY PRIOR THERAPY FROM DREAMM-8: BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE VS POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Güldane Cengiz Seval, 4207764

VALIDATION OF THE IMS–IMWG GENOMIC RISK CLASSIFICATION IN A LARGE COHORT OF PATIENTS WITH TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

EHA Library, Oren Pasvolsky, 4207765

UNRAVELING 1Q⁺/T(4;14) DOUBLE-HIT MYELOMA: CLINICAL AGGRESSIVENESS, EXTRAMEDULLARY RELAPSE, AND MOLECULAR TARGETS FROM A MULTICENTER AND MULTI-OMIC STUDY

EHA Library, Yi Tao, 4207766

FIRST-IN-HUMAN STUDY OF CT0596, AN ALLOGENEIC BCMA CAR T IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIMARY PLASMA CELL LEUKEMIA: SAFETY, EFFICACY, AND PHARMACOKINETIC AT RECOMMENDED DOSE

EHA Library, Juan Du, 4207772

MAGNAZ-TRIAL: A MULTICENTER PHASE II STUDY OF ZANUBRUTINIB TREATMENT IN ANTI-MAG POLYNEUROPATHY

EHA Library, Monique Minnema, 4207773

MOSAIC CHROMOSOMAL ABERRATIONS PRIOR TO AND AT DIAGNOSIS OF MULTIPLE MYELOMA

EHA Library, Cecilie Maeng, 4207776

LONG-TERM SAFETY WITH IPTACOPAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): POOLED ANALYSIS OF DATA FROM PHASE 2 AND 3 STUDIES AND THE ROLL-OVER EXTENSION PROGRAM

EHA Library, Alexander Röth, 4207681

3-YEAR EFFICACY AND SAFETY OF CROVALIMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WHO SWITCHED FROM ECULIZUMAB: LONG-TERM DATA FROM THE PHASE III COMMODORE 1 TRIAL

EHA Library, Fahri Sahin, 4207683

COMPARISONS OF TERMINAL COMPLEMENT INHIBITION WITH POZELIMAB + CEMDISIRAN VERSUS RAVULIZUMAB IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: PHARMACODYNAMIC RESULTS FROM COHORT A

EHA Library, Morag Griffin, 4207684

CARDIOVASCULAR COMORBIDITY BURDEN IN VEXAS SYNDROME: GENOTYPE-STRATIFIED, IMAGING AND LONGITUDINAL FINDINGS FROM THE ITALIAN COHORT

EHA Library, Elisa Meddi, 4207686

CONSISTENT AND SUSTAINED EFFICACY AND SAFETY OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REGARDLESS OF PRIOR HISTORY OF MAJOR ADVERSE VASCULAR EVENTS IN APPLY, APPOINT AND EXTENSION PROGRAM

EHA Library, Bing Han, 4207687

GOLIDOCITINIB MONOTHERAPY IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A PROSPECTIVE, SINGLE-ARM CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY (JACKPOT11)

EHA Library, Jingshi Wang, 4207688

HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION USING A FLUDARABINE-, CYCLOPHOSPHAMIDE-, AND ANTI-LYMPHOCYTE GLOBULIN–BASED CONDITIONING REGIMEN IN FANCONI ANEMIA

EHA Library, Malek Benakli, 4207689

REAL-WORLD EFFECTIVENESS OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AFTER SWITCH FROM C5 INHIBITORS AMONG CEE COUNTRIES

EHA Library, Łukasz Szukalski, 4207691

REAL-WORLD PATIENT-REPORTED TREATMENT BURDEN FROM 106 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE VOICE CROSS-SECTIONAL QUANTITATIVE SURVEY

EHA Library, Shikiko Ueno, 4207692

RAVULIZUMAB MAINTAINS OR IMPROVES RENAL FUNCTION IN REAL-WORLD PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Richard J. Kelly, 4207693

DANICOPAN ADD-ON THERAPY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UK EXPERIENCE

EHA Library, Morag Griffin, 4207695

FIRST-LINE HETROMBOPAG COMBINED WITH IMMUNOSUPPRESSIVE THERAPY FOR PEDIATRIC SEVERE APLASTIC ANEMIA: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

EHA Library, Lingling Fu, 4207696

EFFECTIVENESS AND SAFETY OF IPTACOPAN IN CHINESE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: FIRST REPORT FROM A MULTICENTER AMBISPECTIVE REAL-WORLD COHORT STUDY (IMPACT-PNH CHINA)

EHA Library, Hui Liu, 4207698

LP-005, A BIFUNCTIONAL ANTIBODY, DEMONSTRATES SUSTAINED EFFICACY AND A FAVORABLE SAFETY PROFILE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): UPDATED RESULTS FROM A PHASE Ⅱ STUDY

EHA Library, Guangsheng He, 4207700

RETHINKING THROMBOTIC RISK IN MINOR PNH CLONES: INSIGHTS BEYOND HEMOLYSIS AND CONVENTIONAL RISK FACTORS

EHA Library, Elena Pirvu, 4207702

REPROGRAMMING BCMA-TARGETED CAR-T CELLS THROUGH GAMMA-SECRETASE MODULATION BLOCKS ANTIGEN SHEDDING AND EXTENDS CAR-T LONGEVITY

EHA Library, sheetal Sharma, 4207704

POLYGENIC SCORE PREDICTS MULTIPLE MYELOMA INCIDENCE AND PROGRESSION FROM MGUS ACROSS DIVERSE ANCESTRIES

EHA Library, Carl Jannes Neuse, 4207706

SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE

EHA Library, Antonio Solimando, 4207709

FUNCTIONAL CONSEQUENCES OF TP53 LOSS ACROSS MAJOR IGH TRANSLOCATION SUBTYPES IN MULTIPLE MYELOMA

EHA Library, Sara Cristóbal Vargas, 4207714

A NOVEL HIGH-THROUGHPUT SINGLE-CELL LIPIDOMIC REVEALS POTENTIAL CORRELATION BETWEEN METABOLIC HETEROGENEITY AND VULNERABILITIES WITH CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA

EHA Library, Fujing Zhang, 4207715

CAR-T CELL THERAPY IN ADVANCED MYELOMA WITH EXTRAMEDULLARY DISEASE – AN IN VIVO IMAGING AND MOLECULAR MONITORING STUDY (CARAMEL): CD8+ T CELL INFILTRATION VISUALISED AT PEAK CILTA-CEL EXPANSION

EHA Library, Mark Dowling, 4207716

COEVOLUTION OF NK AND TUMOR CELL STATES ALONG MULTIPLE MYELOMA PROGRESSION FROM PRECURSOR CONDITIONS

EHA Library, Cristina Aquilina, 4207717

A MYELOID-DORMANT METABOLIC TRANSCRIPTOME IDENTIFIES A POOR-PROGNOSIS SUBGROUP IN HYPERDIPLOID MULTIPLE MYELOMA WITH TARGETABLE VULNERABILITIES

EHA Library, Naroa Barrena, 4207718

CONCURRENT RAS/RAF MUTATIONS DEFINE AN ULTRA-HIGH-RISK SUBGROUP IN MULTIPLE MYELOMA WITH GAIN OF CHROMOSOME 1Q

EHA Library, Xueshi YE, 4207719

ONCOGENIC SPLICING OF THE P53-RELATED TUMORSUPPRESSOR ASPP2 PROMOTES DRUG RESISTANCE AND TUMOR PROGRESSION IN MULTIPLE MYELOMA

EHA Library, Kerstin Kampa-Schittenhelm, 4207720

SKP2 INHIBITION INDUCES CELL DEATH IN MULTIPLE MYELOMA IRRESPECTIVE OF P53 STATUS AND SYNERGIZES WITH BORTEZOMIB

EHA Library, Hua Bai, 4207724

MAGNETICALLY INDUCED CELL-PATIENT OR CELL LINE DERIVED XENOGRAFT (MAGIC-PDX/CDX) MODELS FOR THE RAPID ESTABLISHMENT OF MULTIPLE MYELOMA AND DRUG SCREENING

EHA Library, Qianli Jiang, 4207730

PHOSPHORYLATION REGULATES BCMA ABUNDANCE IN MULTIPLE MYELOMA

EHA Library, Sonja Stotz, 4207731

A SYSTEMIC LIPID SIGNATURE DISTINGUISHES AL AMYLOIDOSIS AND SUGGESTS METABOLIC CROSSTALK ACROSS BONE MARROW, CIRCULATION, AND PERIPHERAL TISSUES

EHA Library, Oshrat Hershkovitz-Rokah, 4207735

CHARACTERIZATION OF THE LONG NON-CODING RNA LANDSCAPE IN MULTIPLE MYELOMA REVEALS NOVEL PUTATIVE DRIVER GENES ASSOCIATED WITH POOR OVERALL SURVIVAL

EHA Library, Silke Nielsen, 4207737

STAGE-SPECIFIC DISRUPTION OF ERYTHROPOIESIS LEADS TO ANEMIA IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

EHA Library, Shihui Wang, 4207738

BONE MARROW MICROENVIRONMENT-DEPENDENT INDUCTION OF MTORC1 CAUSES THERAPY RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Maaike Janssens, 4207739

PROGNOSTIC BIOMARKERS BEYOND BONE DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INTEGRATING PROTEOMIC, GENOMIC, AND BONE METABOLISM SIGNATURES

EHA Library, Ioannis Ntanasis-Stathopoulos, 4207740

LIQUID BIOPSY–BASED THREE-DIMENSIONAL TELOMERE PROFILING DISTINGUISHES AL AMYLOIDOSIS FROM MULTIPLE MYELOMA AT DIAGNOSIS

EHA Library, Sabine Mai, 4207744

UTILISING WHOLE PROTEOME ANALYSIS OF EX-VIVO IMID/CELMOD TREATED PRIMARY MYELOMA PATIENT SAMPLES TO UNDERSTAND DRUG RESISTANCE MECHANISMS

EHA Library, Sarah Bird, 4207745

A NEW 3D EX VIVO MODEL OF BONE MARROW FOR PROGNOSIS AND DRUG SCREENING

EHA Library, Emilie Carneiro, 4207747

IMPACT OF SUSTAINED MRD NEGATIVITY ON LONG-TERM OUTCOME OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ENROLLED IN THE RANDOMIZED PHASE 2 FORTE TRIAL

EHA Library, Giuseppe Bertuglia, 4207753

ISATUXIMAB–RD INDUCTION FOLLOWED BY ISA‑R MAINTENANCE COMPARED TO RD INDUCTION FOLLOWED BY R MAINTENANCE IN ELDERLY PTS WITH NDMM WITH EMPHASIS ON FRAIL AND NON-FRAIL PTS (AGMT MM04 TRIAL)

EHA Library, Heinz Ludwig, 4207754

RISK OF AL AMYLOIDOSIS IS ASSOCIATED WITH GRADE OF FREE LIGHT CHAIN ELEVATION AND DURATION OF EXPOSURE

EHA Library, Maximilian Steinhardt, 4207757

BEYOND BONE MARROW: SOLUBLE BCMA AS A LONGITUDINAL SURROGATE FOR MRD AND ITS DISTINCT KINETICS UNDER BISPECIFIC ANTIBODY THERAPY

EHA Library, Masanori Toho, 4207763

DARATUMUMAB RETREATMENT AFTER CONTINUOUS FRONTLINE DARA-VCD WITH BACKBONE SWITCH IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: RESULTS FROM THE MULTICENTER GMMG-DADA STUDY

EHA Library, Tim Richardson, 4207767

A PRELIMINARY STUDY ON THE SAFETY AND EFFICACY OF INTRATHECAL COMBINED WITH INTRAVENOUS CAR-T CELL THERAPY FOR B-CELL MALIGNANCIES WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

EHA Library, Yanli Feng, 4207768

FUNCTIONAL CURE IN WALDENSTROM’S MACROGLOBULINEMIA: DETERMINANTS OF 10-YEAR PROGRESSION-FREE SURVIVAL

EHA Library, Maria Gavriatopoulou, 4207769

WHOLE-BODY [18F]FDG-PET/MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED BY IDECABTAGENE VICLEUCEL FOR DISEASE DETECTION AND PREDICTION OF SURVIVAL.

EHA Library, Bastien JAMET, 4207770

IMPACT OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWING QUADRUPLET THERAPY (DARA-VRD) ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA: A REAL-WORLD DATA ANALYSIS

EHA Library, Lanzhu Yue, 4207771

PERIPHERAL BLOOD MASS SPECTROMETRY REVEALS EARLY RELAPSE DYNAMICS AFTER MAINTENANCE DISCONTINUATION IN MULTIPLE MYELOMA

EHA Library, Anna Pula, 4207774

WHOLE GENOME SEQUENCING OF MULTIPLE MYELOMA CELLS WITH A NOVEL CLINICAL ASSAY UNCOVERS DIVERSITY OF GENETIC ALTERATIONS UNDERLYING IMMUNOTHERAPY RESISTANCE

EHA Library, Bruno Paiva, 4207775

EXTRAPOLATED PROGRESSION-FREE SURVIVAL WITH BELANTAMAB MAFODOTIN/LENALIDOMIDE/DEXAMETHASONE EXCEEDS 7 YEARS IN INTERMEDIATE-FIT AND FRAIL, TRANSPLANT-INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Evangelos Terpos, 4207777

EARLY RESOLUTION OF TALQUETAMAB ORAL SIDE EFFECTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED WATERLESS EMPIRICAL TASTE TEST (WETT) AND PATIENT REPORTED OUTCOMES (PRO) DATA FROM TALISMAN

EHA Library, Niels W C J van de Donk, 4207778